Skip to search formSkip to main contentSkip to account menu

Dovitinib Lactate

Known as: 4-Amino-5-fluoro-3-(6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one mono 2-hydroxypropanoate Hydrate, RTK Inhibitor TKI258 
The orally bioavailable lactate salt of a benzimidazole-quinolinone compound with potential antineoplastic activity. Dovitinib strongly binds to… 
National Institutes of Health

Related topics

Related topics

8 relations
CHIR-258FGFR3 protein, humanFLT3 protein, humanPlatelet-Derived Growth Factor Receptor

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Abstract 780:In vitroscreening of individual human neuroendocrine tumors for their angiogenic response to tyrosine kinase inhibitors
Background: Human neuroendocrine tumors (NETs) are highly vascular in nature and reliant on multiple receptor tyrosine kinases… 
2010
2010
Gateways to clinical trials.
(-)-Epigallocatechin gallate, Abafungin, ACE-031, Adapalene/benzoyl peroxide, AE-37, Aflibercept, AGS-003, Albiglutide… 
2009
2009
TKI258 (dovitinib lactate) in metastatic renal cell carcinoma (mRCC) patients refractory to approved targeted therapies: A phase I/II dose finding and biomarker study.
3563 Background: TKI258 is a potent receptor tyrosine kinase inhibitor (TKI) that selectively targets VEGFR, PDGFR, FGFR, CSF1R… 
2009
2009
Effect of TKI258 on plasma biomarkers and pharmcokinetics in patients with advanced melanoma.
9020 Background: TKI258 (dovitinib lactate), is a multi-tyrosine kinase inhibitor of VEGF receptors-1,2,3, FGF receptors-1, 2, 3… 
2009
2009
TKI258, a novel, multitargeted tyrosine kinase inhibitor for the treatment of breast cancer.
e14625 TKI258 (4-amino-5-fluor-3-[5-(4-metylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one, formerly known as CHIR258… 
2008
2008
A phase I dose finding and biomarker study of TKI258 (dovitinib lactate) in patients with advanced melanoma
9026 Background: TKI258 is an inhibitor of type III to V RTKs including VEGF-Rs, FGF-Rs (FGF-R1, 2 and 3), PDGFR-β, c- KIT and… 
2008
2008
The pharmacodynamic effect of TKI258 on plasma biomarkers of angiogenesis in patients with AML and advanced melanoma
14680 Background: TKI258 (dovitinib lactate), is a multi-tyrosine kinase inhibitor of VEGF receptors-1,2,3, FGF receptors-1, 2, 3… 
2008
2008
Modelling TKI258 exposure and biomarker response in support of phase I dosing schedule finding
14691 Background: TKI258 (dovitinib lactate), an inhibitor of type III-V receptor tyrosine kinases (RTK), is being evaluated in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)